T
MNTA

Tahithromos’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Tahithromos’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-68,456
Closed -$776K – 45
2014
Q3 		$776K Buy
+68,456
New +$781K 0.2% 35

Other funds holding MNTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Tahithromos's MNTA Position: Q4 2014 in Review

Tahithromos sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2014, closing a stake of 68,456 shares — an estimated $776K sold.

Tahithromos first reported a position in MNTA in Q3 2014 and held it in 1 quarter. The position peaked at $776K in Q3 2014. 148 funds tracked by Wall St. Rank hold MNTA as of Q4 2014.

  • Tahithromos reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Tahithromos sold 68,456 Momenta Pharmaceuticals, Inc. shares in Q4 2014, an estimated $776K.
  • Tahithromos first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2014 and held it in 1 quarter.
  • Tahithromos's Momenta Pharmaceuticals, Inc. position peaked at $776K in Q3 2014.
  • 148 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2014.

Based on Tahithromos's 13F filing for Q4 2014, filed 22 Jan 2015.